- Home
- AVDX vs LGND Comparison
AVDX vs LGND Comparison
Compare AVDX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- LGND
- Stock Information
- Founded
- AVDX 2000
- LGND 1987
- Country
- AVDX United States
- LGND United States
- Employees
- AVDX N/A
- LGND N/A
- Industry
- AVDX EDP Services
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- LGND Health Care
- Exchange
- AVDX Nasdaq
- LGND Nasdaq
- Market Cap
- AVDX 2.0B
- LGND 2.0B
- IPO Year
- AVDX 2021
- LGND 1992
- Fundamental
- Price
- AVDX $9.84
- LGND $124.30
- Analyst Decision
- AVDX Hold
- LGND Strong Buy
- Analyst Count
- AVDX 15
- LGND 8
- Target Price
- AVDX $10.04
- LGND $144.71
- AVG Volume (30 Days)
- AVDX 2.5M
- LGND 139.7K
- Earning Date
- AVDX 07-30-2025
- LGND 08-05-2025
- Dividend Yield
- AVDX N/A
- LGND N/A
- EPS Growth
- AVDX N/A
- LGND N/A
- EPS
- AVDX 0.01
- LGND N/A
- Revenue
- AVDX $441,284,000.00
- LGND $181,488,000.00
- Revenue This Year
- AVDX $5.63
- LGND $18.41
- Revenue Next Year
- AVDX $9.83
- LGND $18.87
- P/E Ratio
- AVDX $1,102.80
- LGND N/A
- Revenue Growth
- AVDX 10.46
- LGND 53.40
- 52 Week Low
- AVDX $6.61
- LGND $81.74
- 52 Week High
- AVDX $12.93
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- AVDX 68.75
- LGND 64.68
- Support Level
- AVDX $9.83
- LGND $120.68
- Resistance Level
- AVDX $9.81
- LGND $127.07
- Average True Range (ATR)
- AVDX 0.02
- LGND 3.76
- MACD
- AVDX -0.02
- LGND 0.86
- Stochastic Oscillator
- AVDX 84.62
- LGND 81.95
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.